Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

Crizotinib, a first-line anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor, has shown promising results for the treatment of locally advanced and metastatic lung cancer presenting the ALK rearrangement. On the other hand, secondary organizing pneumonia (OP) caused by anti-cancer drugs has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Asai, Nobuhiro, Yokoi, Toyoharu, Yamaguchi, Etsuro, Kubo, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: September, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224257/
https://www.ncbi.nlm.nih.gov/pubmed/25408663
http://dx.doi.org/10.1159/000366516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224257/
https://www.ncbi.nlm.nih.gov/pubmed/25408663
http://dx.doi.org/10.1159/000366516

Ejemplares similares